Scopia snags two board seats at Acorda following stock purchase; BeiGene nabs second indication for Revlimid in China
→ A hedge fund in New York has notified Acorda Therapeutics $ACOR that it owns nearly 8.5 million shares of the company’s common stock …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
